Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25401801 | 1.00 | NPC1 (0.44) | NPC1RAB9ACTRB1PPARGMAOA | |
| SCHEMBL25400056 | 0.92 | MMP13 (0.44) | RAB9ACTRB1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL25399015 | 0.92 | NPC1 (0.43) | NPC1RAB9AMAOAKMT2AGAA | |
| SCHEMBL25399012 | 0.92 | NPC1 (0.43) | NPC1RAB9AMAOAKMT2AGAA | |
| SCHEMBL25400059 | 0.92 | MMP13 (0.44) | RAB9ACTRB1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL25398363 | 0.91 | CTRB1 (0.52) | CTRB1PSMB5PSMB8 | |
| SCHEMBL25398364 | 0.91 | CTRB1 (0.52) | CTRB1PSMB5PSMB8 | |
| SCHEMBL25398233 | 0.86 | PSMB5 (0.40) | CTRB1PSMB5PSMB8 | |
| SCHEMBL25398231 | 0.86 | PSMB5 (0.40) | CTRB1PSMB5PSMB8 | |
| SCHEMBL25403137 | 0.85 | CTRB1 (0.41) | CTRB1PPARGEPHX2PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | NPC1 208/4885RAB9A 715/4885CTRB1 163/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | NPC1 180/4885RAB9A 931/4885CTRB1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.